References
- Athale U, Siciliano S, Thabane L, et al. Epidemiology and clinical risk factors predisposing to thromboembolism in children with cancer. Pediatr Blood Cancer. 2008;51(6):792–797. doi:10.1002/pbc.21734
- Pelland-Marcotte MC, Pole JD, Kulkarni K, et al. Thromboembolism incidence and risk factors in children with cancer: a population-based cohort study. Thromb Haemost. 2018;118(9):1646–1655. doi:10.1055/s-0038-1668543
- Barg AA, Kenet G. Cancer-associated thrombosis in pediatric patients. Thromb Res. 2020;191(Suppl 1):S22–S25. doi:10.1016/S0049-3848(20)30392-3
- Athale UH, Laverdiere C, Nayiager T, et al. Evaluation for inherited and acquired prothrombotic defects predisposing to symptomatic thromboembolism in children with acute lymphoblastic leukemia: a protocol for a prospective, observational, cohort study. BMC Cancer. 2017;17(1):313. doi:10.1186/s12885-017-3306-5
- Nowak-Göttl U, Heinecke A, von Kries R, et al. Thrombotic events revisited in children with acute lymphoblastic leukemia: impact of concomitant Escherichia coli asparaginase/prednisone administration. Thromb Res. 2001;103(3):165–172. doi:10.1016/s0049-3848(01)00286-9
- Barzilai-Birenboim S, Arad-Cohen N, Nirel R, et al. Thrombophilia screening and thromboprophylaxis may benefit specific ethnic subgroups with paediatric acute lymphoblastic leukaemia. Br J Haematol. 2019;184(6):994–998. doi:10.1111/bjh.15752
- Mitchell LG, Sutor AH, Andrew M. Hemostasis in childhood acute lymphoblastic leukemia: coagulopathy induced by disease and treatment. Semin Thromb Hemost. 1995;21(4):390–401. doi:10.1055/s-2007-1000660
- Pelland-Marcotte MC, Kulkarni K, Athale UH, et al. Thrombosis is associated with worse survival in children with acute lymphoblastic leukemia: a report from CYP-C. Am J Hematol. 2021;96(7):796–804. doi:10.1002/ajh.26193
- Monagle P, Chan AKC, Goldenberg NA, et al. Antithrombotic therapy in neonates and children: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 Suppl):e737S–e801S. doi:10.1378/chest.11-2308
- Monagle P, Cuello CA, Augustine C, et al. American society of hematology 2018 guidelines for management of venous thromboembolism: treatment of pediatric venous thromboembolism. Blood Adv. 2018;2(22):3292–3316. doi:10.1182/bloodadvances.2018024786
- Palumbo JS, Lensing AWA, Brandão LR, et al. Anticoagulation in pediatric cancer-associated venous thromboembolism: a subgroup analysis of EINSTEIN-Jr. Blood Adv. 2022;6(22):5821–5828. doi:10.1182/bloodadvances.2022008160
- Barg AA, Levy-Mendelovich S, Gilad O, et al. Rivaroxaban treatment among children with cancer-associated thromboembolism: real-world data. Pediatr Blood Cancer. 2022;69(10):e29888.
- Mitchell LG, Goldenberg NA, Male C, et al. Definition of clinical efficacy and safety outcomes for clinical trials in deep venous thrombosis and pulmonary embolism in children. J Thromb Haemost. 2011;9(9):1856–1858. doi:10.1111/j.1538-7836.2011.04433.x
- Greiner J, Schrappe M, Claviez A, et al. THROMBOTECT - a randomized study comparing low molecular weight heparin, antithrombin and unfractionated heparin for thromboprophylaxis during induction therapy of acute lymphoblastic leukemia in children and adolescents. Haematologica. 2019;104(4):756–765. doi:10.3324/haematol.2018.194175
- O'Brien SH, Li D, Mitchell LG, et al. PREVAPIX-ALL: apixaban compared to standard of care for prevention of venous thrombosis in paediatric acute lymphoblastic leukaemia (ALL)-rationale and design. Thromb Haemost. 2019;119(5):844–853. doi:10.1055/s-0039-1679938
- O'Brien SR, Lew G, Newburger J, et al. PREVAPIX-ALL: phase 3 study of the safety and efficacy of apixaban for thromboprophylaxis versus standard of care in newly diagnosed pediatric acute lymphoblastic leukemia or lymphoma (ALL/LL). 2022.